Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: M05BA06

Destara(ibandronic acid)

Hypercalcemia;Cancer

Marketing Authorisation Holder: Roche Registration Ltd.

EMA Authorisation: 25/06/1996

INN: ibandronic acid

Indication

Treatment of tumour-induced hypercalcaemia with or without metastases.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Destara — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.